NCT00937781

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
307

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2011

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 10, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 13, 2009

Completed
1.6 years until next milestone

Study Start

First participant enrolled

February 8, 2011

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 8, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 8, 2011

Completed
Last Updated

May 17, 2017

Status Verified

May 1, 2017

Enrollment Period

6 months

First QC Date

July 10, 2009

Last Update Submit

May 16, 2017

Conditions

Melanoma (Skin)

Keywords

stage III melanomarecurrent melanoma

Outcome Measures

Primary Outcomes (1)

  • Prognostic role of several biomarkers on the outcome associated with melanoma using IHC

    1 month

Interventions

RNA analysisGENETIC
gene expression analysisGENETIC
microarray analysisGENETIC
polymerase chain reactionGENETIC
immunohistochemistry staining methodOTHER
laboratory biomarker analysisOTHER

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Samples submitted for research from patients enrolled on E1690

DISEASE CHARACTERISTICS: * Diagnosis of melanoma * No metastatic disease at diagnosis * Treated on protocol EST-1690 * Primary tumor tissue specimens available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

MeSH Terms

Conditions

Melanoma

Interventions

Gene Expression ProfilingMicroarray AnalysisPolymerase Chain ReactionImmunohistochemistry

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Genetic TechniquesInvestigative TechniquesMicrochip Analytical ProceduresNucleic Acid Amplification TechniquesHistocytochemistryCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHistological TechniquesImmunologic Techniques

Study Officials

  • Mohammed Kashani-Sabet, MD

    University of California, San Francisco

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2009

First Posted

July 13, 2009

Study Start

February 8, 2011

Primary Completion

August 8, 2011

Study Completion

August 8, 2011

Last Updated

May 17, 2017

Record last verified: 2017-05